1. Type 1 insulin-like growth factor receptor monoclonal antibody (HX-1162) treatment for liver cancer
- Author
-
Tie-Chui Zhu, Xue-Hui Chen, Hua Peng, Xiao-Gang Weng, Hui-Qing Fu, Su-Mei Jin, and Zhi-Qiang Li
- Subjects
business.industry ,medicine.drug_class ,Growth factor ,medicine.medical_treatment ,apoptosis ,hepatocellular carcinoma ,Insulin-Like Growth Factor Receptor ,medicine.disease ,Monoclonal antibody ,OncoTargets and Therapy ,Metastasis ,Oncology ,Apoptosis ,Cancer cell ,Immunology ,medicine ,Cancer research ,Pharmacology (medical) ,IGF ,Liver cancer ,business ,Receptor ,IGF-1R ,Original Research - Abstract
Xue-Hui Chen, Zhi-Qiang Li, Hua Peng, Su-Mei Jin, Hui-Qing Fu, Tie-Chui Zhu, Xiao-Gang WengThe First Affiliated Hospital of Xinxiang Medical University, Weihui, People's Republic of ChinaAbstract: One of the most important molecules mediating the proliferation, growth, and metastasis of cancer cells is insulin-like growth factor (IGF), with its receptor IGF-R1. Here, we describe the potential of an IGF-1R monoclonal antibody, HX-1162, on liver cancer apoptosis in vitro and in vivo. We found that HX-1162 could induce the apoptosis of cultured liver cancer cells. Additionally, HX-1162 treatment inhibited the tumor growth after cancer cell grafting and enhanced the cell apoptosis inside the tumor tissue. We conclude that IGF-R1 targeting therapy provides a new avenue toward treating liver cancer.Keywords: IGF, IGF-R1, apoptosis, hepatocellular carcinoma
- Published
- 2013